Here, we introduced the albumin binder palmitic acid into the 177Lu-3PRGD2 peptide structure to obtain the long-acting radiopharmaceutical 177Lu-Palm-3PRGD2 and evaluated its therapeutic efficacy in a tumor model. Here, ALB is linked to neoplasm.